var data={"title":"Naproxen: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Naproxen: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6629?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=naproxen-drug-information\" class=\"drug drug_general\">see &quot;Naproxen: Drug information&quot;</a> and <a href=\"topic.htm?path=naproxen-patient-drug-information\" class=\"drug drug_patient\">see &quot;Naproxen: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709165\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious cardiovascular thrombotic events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI), and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Naproxen is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious gastrointestinal bleeding, ulceration, and perforation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199854\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aleve [OTC];</li>\n      <li>All Day Relief [OTC];</li>\n      <li>Anaprox DS;</li>\n      <li>EC-Naprosyn;</li>\n      <li>EnovaRX-Naproxen;</li>\n      <li>Equipto-Naproxen;</li>\n      <li>Flanax Pain Relief;</li>\n      <li>Flanax Pain Relief [OTC];</li>\n      <li>GoodSense Naproxen Sodium [OTC];</li>\n      <li>Mediproxen [OTC];</li>\n      <li>Naprelan;</li>\n      <li>Naprosyn;</li>\n      <li>Naproxen Comfort Pac;</li>\n      <li>Naproxen DR;</li>\n      <li>Naproxen Kit [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199855\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aleve;</li>\n      <li>Anaprox;</li>\n      <li>Anaprox DS;</li>\n      <li>Maxidol;</li>\n      <li>Naprosyn;</li>\n      <li>Pediapharm Naproxen Suspension;</li>\n      <li>PMS-Naproxen Suppository [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054290\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Nonopioid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antipyretic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nonsteroidal Anti-inflammatory Drug (NSAID), Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054283\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=naproxen-drug-information\" class=\"drug drug_general\">see &quot;Naproxen: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:<b> Note:</b> Dosage expressed as naproxen base; 200 mg naproxen base is equivalent to 220 mg naproxen sodium. In pediatric patients, all dosing is for the immediate release preparations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesia/pain, mild to moderate:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &lt;60 kg: Limited data available: Oral: 5 to 6 mg/kg/dose every 12 hours; maximum daily dose: 1,000 mg/day (Berde 2002); doses as high as 10 mg/kg/dose have also been recommended (APS 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &ge;60 kg: Limited data available: Oral: 250 to 375 mg twice daily; maximum daily dose: 1,000 mg/day (Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>OTC labeling</i>: Children &ge;12 years and Adolescents: Oral: 200 mg every 8 to 12 hours; if needed may take 400 mg for the initial dose; maximum daily dose: 600 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Fever: </b>\n      <i>OTC labeling:</i> Children &ge;12 years and Adolescents: Oral: 200 mg every 8 to 12 hours; if needed may take 400 mg for the initial dose; maximum daily dose: 600 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis</b>: Children and Adolescents: Oral: 10 to 15 mg/kg/<b>day</b> in 2 divided doses; Maximum daily dose: 1,000  mg/day (Hollingsworth 1993; Kliegman 2016; Litalien 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ankylosing spondylitis</b>: Limited data available: Children and Adolescents: Oral: 15 to 20 mg/kg/<b>day</b> in 2 divided doses; maximum daily dose: 1,500 mg/day; adult dosing suggests limiting this maximum daily dose to &lt;6 months of therapy (APS 2008; Kliegman 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Dosage expressed as naproxen base; 200 mg naproxen base is equivalent to 220 mg naproxen sodium. For relief of acute pain, naproxen sodium may be preferred due to more rapid absorption and onset; naproxen base may also be used; however, extended release naproxen is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ankylosing spondylitis, osteoarthritis, rheumatoid arthritis:</b> Oral: 500 to 1,000 mg daily in 2 divided doses; in patients who require higher level of anti-inflammatory/analgesic activity and have tolerated lower doses, may increase to 1,500 mg/day for a limited time period (&lt;6 months)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Naproxen extended-release tablets:</i> Oral: Initial: 750 to 1,000 mg once daily; in patients who require higher level of anti-inflammatory/analgesic activity and have tolerated lower doses, may temporarily increase to 1,500 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gout, acute:</b> Oral: Initial: 750 mg, followed by 250 mg every 8 hours until attack subsides</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Naproxen extended release tablets:</i> Oral: Initial: 1,000 to 1,500 mg once daily followed by 1,000 mg once daily until attack subsides</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pain (mild to moderate), dysmenorrhea, acute tendonitis, bursitis:</b> Oral: Initial: 500 mg, followed by 500 mg every 12 hours or 250 mg every 6 to 8 hours; maximum daily dose: Day 1: 1,250 mg; subsequent daily doses should not exceed 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Naproxen extended release tablets:</i> Oral: Initial: 1,000 mg once daily; may temporarily increase to 1,500 mg once daily if greater pain relief is needed. Dose should be subsequently reduced to a maximum of 1,000 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>OTC labeling:</b> Pain, fever: Oral: 200 mg every 8 to 12 hours; if needed, may take 400 mg for the initial dose; maximum: 400 mg in any 8- to 12-hour period or 600 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling: Children &ge;2 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution and consider using a reduced dose. Use is not recommended in patients with moderate renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Use is not recommended; avoid use in patients with advanced renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">KDIGO 2012 guidelines provide the following recommendations for NSAIDs: Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution and consider using a reduced dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199830\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aleve: 220 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EnovaRX-Naproxen: 10% (60 g, 120 g) [contains cetyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Equipto-Naproxen: 10% (120 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flanax Pain Relief: 500 mg [contains cetearyl alcohol, cremophor el, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naproxen Comfort Pac: 500 mg [contains methylparaben, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naprosyn: 125 mg/5 mL (473 mL) [contains fd&amp;c yellow #6 (sunset yellow), methylparaben, sorbitol; pineapple-orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (473 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naprosyn: 250 mg [DSC], 375 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naprosyn: 500 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naproxen Kit: 500 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 375 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aleve: 220 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">All Day Relief: 220 mg [DSC] [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">All Day Relief: 220 mg [gluten free; contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anaprox DS: 550 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flanax Pain Relief: 220 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Naproxen Sodium: 220 mg [gluten free; contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mediproxen: 220 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 220 mg, 275 mg, 550 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EC-Naprosyn: 375 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naproxen DR: 375 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naprelan: 375 mg, 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 375 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199815\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23884418\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=naproxen-drug-information\" class=\"drug drug_general\">see &quot;Naproxen: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EnovaRX-Naproxen and Equipto-Naproxen creams are compounded from a kit.  Refer to manufacturer&rsquo;s package insert for compounding instructions. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naproxen Comfort Pac kit contains naproxen tablets and Duraflex Comfort Gel</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flanax Pain Relief kit contains naproxen tablets and Flanax Liniment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874744\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Anaprox, Anaprox DS: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf#page=22&amp;token=oMzvJRCAEUzTx0mXE+YlZfHIwDkJKKLlXhJRhlQLG8hx2VTTvuO3vdO3Y7uWHVTlPLuv5UT4Z0rcel6W61xiLiqJ3ufw8B9w6CUJa93QQCz9E8LOQ33KccqTRDhhIre7rwC1JCwUsNIWoeWxLU0oqw==&amp;TOPIC_ID=12630\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf#page=22</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">EC-Naprosyn: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf#page=22&amp;token=oMzvJRCAEUzTx0mXE+YlZfHIwDkJKKLlXhJRhlQLG8hx2VTTvuO3vdO3Y7uWHVTlPLuv5UT4Z0rcel6W61xiLiqJ3ufw8B9w6CUJa93QQCz9E8LOQ33KccqTRDhhIre7rwC1JCwUsNIWoeWxLU0oqw==&amp;TOPIC_ID=12630\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf#page=22</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Naprelan: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM280324.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68jqQc21xnM3irwc38J8t7Xg==&amp;TOPIC_ID=12630\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM280324.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Naprosyn suspension: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018965s025lbl.pdf#page=21&amp;token=qIYHT7ARoJQvMI5VpdMEZz3FwJyhixrIekVx2lfER9WozQW3KzvGGAsNtV6xHSbfP6tC0eRuzf5RVlH40jKblyd20lto+41urZZW6RcQYxLv6wwDQEvNzSr1Ivj1OFEw&amp;TOPIC_ID=12630\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018965s025lbl.pdf#page=21</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Naprosyn tablets: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf#page=22&amp;token=oMzvJRCAEUzTx0mXE+YlZfHIwDkJKKLlXhJRhlQLG8hx2VTTvuO3vdO3Y7uWHVTlPLuv5UT4Z0rcel6W61xiLiqJ3ufw8B9w6CUJa93QQCz9E8LOQ33KccqTRDhhIre7rwC1JCwUsNIWoeWxLU0oqw==&amp;TOPIC_ID=12630\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf#page=22</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">NSAID: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WJqYrx1xLSb8GxuJFaqJ8Kg==&amp;TOPIC_ID=12630\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf#page=22</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054294\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with food, milk, or antacids to decrease GI adverse effects. Shake suspension well before use. Do not chew, crush, or break delayed or controlled release tablet, swallow whole. Separate administration of naproxen and antacids, sucralfate, or cholestyramine by 2 hours. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199849\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); suspension should not be exposed to excessive heat (&gt;40&deg;C [104&deg;F]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054293\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prescription strength products:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release products: Relief of the signs and symptoms of juvenile idiopathic arthritis (JIA) (FDA approved in ages &ge;2 years and adults); relief of the signs and symptoms of acute gout, ankylosing spondylitis, bursitis, osteoarthritis, rheumatoid arthritis, and tendonitis (FDA approved in adults); management of mild to moderate pain (FDA approved in adults); management of primary dysmenorrhea (FDA approved in adults). <b>Note:</b> Approval in pediatric patients may vary, consult product-specific labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release products: Relief of the signs and symptoms of acute gout, ankylosing spondylitis, bursitis, osteoarthritis, rheumatoid arthritis, and tendonitis; management of mild to moderate pain; management of primary dysmenorrhea (All indications FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC products: Relief of minor aches and pains due to arthritis, muscular aches, backache, menstrual cramps, headache, or toothache (FDA approved in ages &ge;12 years and adults); fever reduction  (FDA approved in ages &ge;12 years and adults). <b>Note:</b> Approved ages and uses for generic products may vary; consult labeling for specific information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199915\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Naproxen may be confused with Natacyn, Nebcin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Anaprox may be confused with Anaspaz, Avapro</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Naprelan may be confused with Naprosyn</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Naprosyn may be confused with Natacyn, Nebcin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Naproxen is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, older than 75 years or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flogen [Mexico] may be confused with Flovent brand name for fluticasone [US, Canada]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flogen [Mexico] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [US, Canada], and perfloxacin [Philippines]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199912\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Edema, palpitations </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, drowsiness, headache, vertigo </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis, ecchymoses, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Fluid retention, increased thirst </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gastrointestinal hemorrhage, gastrointestinal perforation, gastrointestinal ulcer, heartburn, nausea, stomatitis, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, hemolysis, prolonged bleeding time, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Auditory disturbance, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal function abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abnormal dreams, agranulocytosis, alopecia, anaphylactoid reaction, anaphylaxis, angioedema, aphthous stomatitis, aseptic meningitis, asthma, blurred vision, cardiac arrhythmia, cardiac failure, cognitive dysfunction, colitis, coma, confusion, conjunctivitis, cystitis, depression, dysuria, eosinophilia, eosinophilic pneumonitis, erythema multiforme, exfoliative dermatitis, fever, glossitis, granulocytopenia, hallucination, hematemesis, hepatic failure, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hyperglycemia, hypertension, hypoglycemia, hypotension, infection, interstitial nephritis, melena, jaundice, leukopenia, lymphadenopathy, menstrual disease, malaise,  myalgia, myasthenia, myocardial infarction, oliguria, pancreatitis, pancytopenia, paresthesia, pneumonia, polyuria, proteinuria, rectal hemorrhage, renal failure, renal papillary necrosis, respiratory depression, sepsis, skin photosensitivity, Stevens-Johnson syndrome, tachycardia, seizure, syncope, thrombocytopenia, toxic epidermal necrolysis, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199837\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to naproxen (eg, anaphylactic reactions, serious skin reactions) or any component of the formulation; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; use in the setting of coronary artery bypass graft (CABG) surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Active gastric, duodenal, or peptic ulcers; active GI bleeding; cerebrovascular bleeding or other bleeding disorders; active GI inflammatory disease; severe liver impairment or active liver disease; severe renal impairment (CrCl &lt;30 mL/minute) or deteriorating renal disease; severe uncontrolled heart failure; known hyperkalemia; third trimester of pregnancy; breast-feeding; inflammatory lesions or recent bleeding of the rectum or anus (suppository only); use in patients &lt;16 years of age (suppository only); use in patients &lt;18 years of age (naproxen enteric coated and sustained release tablets and naproxen sodium tablets); use in children &lt;2 years (naproxen tablets and suspension).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199819\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with &quot;aspirin triad&quot; (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Contraindicated in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events:<b> [US Boxed Warning]: NSAIDs cause an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including MI and stroke. Risk may occur early during treatment and may increase with duration of use.</b> Relative risk appears to be similar in those with and without known cardiovascular disease or risk factors for cardiovascular disease; however, absolute incidence of serious cardiovascular thrombotic events (which may occur early during treatment) was higher in patients with known cardiovascular disease or risk factors and in those receiving higher doses. New-onset hypertension or exacerbation of hypertension may occur (NSAIDs may also impair response to ACE inhibitors, thiazide diuretics, or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in patients with hypertension. May cause sodium and fluid retention, use with caution in patients with edema. Avoid use in heart failure (ACCF/AHA [Yancy 2013]). Avoid use in patients with a recent MI unless benefits outweigh risk of cardiovascular thrombotic events. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal events:<b> [US Boxed Warning]: NSAIDs cause increased risk of serious gastrointestinal inflammation, ulceration, bleeding, and perforation (may be fatal); elderly patients and patients with history of peptic ulcer disease and/or GI bleeding are at greater risk of serious GI events. These events may occur at any time during therapy and without warning.</b> Avoid use in patients with active GI bleeding. Use caution with a history of GI ulcers, concurrent therapy known to increase the risk of GI bleeding (eg, aspirin, anticoagulants and/or corticosteroids, selective serotonin reuptake inhibitors), advanced hepatic disease, coagulopathy, smoking, use of alcohol, or in elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Transaminase elevations have been reported with use; closely monitor patients with any abnormal LFT. Rare (sometimes fatal) severe hepatic reactions (eg, fulminant hepatitis, hepatic necrosis, hepatic failure) have occurred with NSAID use; discontinue immediately if signs or symptoms of hepatic disease develop or if systemic manifestations occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation (usually reversible). Patients with impaired renal function, dehydration, hypovolemia, heart failure, hepatic impairment, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Long-term NSAID use may result in renal papillary necrosis and other renal injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: NSAIDs may cause potentially fatal serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); may occur without warning; discontinue use at first sign of skin rash (or any other hypersensitivity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe and potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery bypass graft surgery: <b>[US Boxed Warning]: Use is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</b> Risk of MI and stroke may be increased with use following CABG surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; patients with advanced hepatic disease are at an increased risk of GI bleeding with NSAIDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Avoid use in patients with advanced renal disease; discontinue use with persistent or worsening abnormal renal function tests.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients are at greater risk for serious GI, cardiovascular, and/or renal adverse events; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not for self-medication (OTC use) in children &lt;12 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, asthma, high blood pressure, heart or kidney disease, other serious medical problems, are currently taking a diuretic, anticoagulant, other NSAIDs, or are &ge;60 years of age. Recommended dosages and duration should not be exceeded, due to an increased risk of GI bleeding, MI, and stroke. Patients should stop use and consult a healthcare provider if symptoms get worse, newly appear, or continue; if an allergic reaction occurs; if feeling faint, vomit blood or have bloody/black stools; if having difficulty swallowing or heartburn, or if fever lasts for &gt;3 days or pain &gt;10 days. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26018318\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pseudoporphyria (ie, increased skin fragility and blistering with scarring in sun-exposed skin) has been reported in naproxen-treated children with JIA (reported incidence, 12%); discontinue therapy if this occurs (Lang 1994).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199900\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199824\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12630&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Naproxen may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Naproxen may increase the serum concentration of Apixaban. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexibuprofen: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAIDs).  Avoid the use of diclofenac/misoprostol with other NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbinac: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pelubiprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <b> Exceptions: </b>Choline Magnesium Trisalicylate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of a gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants (Tertiary Amine): May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zaltoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199850\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Naproxen absorption rate/levels may be decreased if taken with food. Management: Administer with food, milk, or antacids to decrease GI adverse effects. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7696306\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Naproxen crosses the placenta (Brogden 1975). Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013). Because NSAIDs may cause premature closure of the ductus arteriosus, product labeling for naproxen specifically states use should be avoided starting at 30-weeks gestation. Use of NSAIDs can be considered for the treatment of mild rheumatoid arthritis flares in pregnant women; however, use should be minimized or avoided early and late in pregnancy (Bermas 2014; Saavedra Salinas 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in women having difficulty conceiving or those undergoing investigation of fertility. The use of NSAIDs close to conception may be associated with an increased risk of miscarriage (Bloor 2013; Bermas 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054289\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, platelets, BUN, serum creatinine, liver enzymes, occult blood loss, periodic ophthalmologic exams, hemoglobin, hematocrit, blood pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199818\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199836\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Analgesic: 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Analgesic: &lt;12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Almost 100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 0.16 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99% to albumin; increased free fraction in elderly </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively metabolized in the liver to 6-0-desmethyl naproxen; parent drug and desmethyl metabolite undergo further metabolism to their respective acylglucuronide conjugated metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Range: 8 to 17 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 8 to 14 years: 8 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Normal renal function: 12 to 17 hours; Moderate-to-severe renal impairment: ~15 to 21 hours (Anttila 1980)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablets, naproxen: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablets, naproxen sodium: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablets, delayed-release (empty stomach): 4 to 6 hours; range: 2 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablets, delayed-release (with food): 12 hours; range: 4 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suspension: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suppository [Canadian product]: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (95%; primarily as metabolites); feces (&le;3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199839\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Aleve Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mg (160): $20.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Equipto-Naproxen External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (120 g): $575.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Naproxen Comfort Pac Combination)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $74.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Naprosyn Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (473 mL): $1,149.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Naproxen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (473 mL): $925.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Naprelan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">375 mg (100): $2,613.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (75): $1,795.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (30): $831.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Naproxen Sodium ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">375 mg (100): $2,152.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (75): $1,614.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (EC-Naprosyn Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">375 mg (100): $275.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $336.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Aleve Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mg (320): $19.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Anaprox DS Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">550 mg (100): $558.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Flanax Pain Relief Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mg (10): $1.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mediproxen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mg (1): $0.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Naprosyn Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $355.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Naproxen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $77.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">375 mg (100): $106.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $129.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Naproxen Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mg (50): $4.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">275 mg (100): $229.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">550 mg (100): $356.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199841\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acusprain (ZA);</li>\n      <li>Aflamax (PE);</li>\n      <li>Aleve (AT, EE, HU, LU, PL, PY, SG, UY);</li>\n      <li>Anaflex (BD);</li>\n      <li>Anexopen (GR);</li>\n      <li>Antalgin (ES);</li>\n      <li>Apranax (CR, DO, FR, GT, HN, HU, LU, NI, PA, RU, SV, VE, VN);</li>\n      <li>Aprelax (PH);</li>\n      <li>Apronax (EC);</li>\n      <li>Artagen (IN);</li>\n      <li>Artroxen (IT);</li>\n      <li>Bei Li (CN);</li>\n      <li>Bonyl (DK);</li>\n      <li>Bumaflex N (PY);</li>\n      <li>Clerinax (PY);</li>\n      <li>Crysanal (AU);</li>\n      <li>Daprox (DK);</li>\n      <li>Dysmenalgit (DE);</li>\n      <li>Emox (LV);</li>\n      <li>Femex (NL);</li>\n      <li>Flanax (BR, EC);</li>\n      <li>Floginax (IT);</li>\n      <li>Gibixen (IT);</li>\n      <li>Inza (AU, HK);</li>\n      <li>Iraxen (PE);</li>\n      <li>Laser (IT);</li>\n      <li>Leniartil (IT);</li>\n      <li>Licorax (KR);</li>\n      <li>Lundiran (ES);</li>\n      <li>Momen (ES);</li>\n      <li>Momendol (IE, MT);</li>\n      <li>Nafasol (ZA);</li>\n      <li>Naflax (PH);</li>\n      <li>Naldorex (RO);</li>\n      <li>Nalgedol (LV);</li>\n      <li>Nalgesin (BG, HR, LV);</li>\n      <li>Nalhezin (UA);</li>\n      <li>Naposin (TW);</li>\n      <li>Napoxen (PH);</li>\n      <li>Napren E (NO);</li>\n      <li>Naprex (PK);</li>\n      <li>Naprium (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Naprius (IT);</li>\n      <li>Napro (LK);</li>\n      <li>Napro A (BD);</li>\n      <li>Naprodil (MX);</li>\n      <li>Naproff (UA);</li>\n      <li>Naproflex (TH);</li>\n      <li>Naprontag (AR);</li>\n      <li>Naprorex (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MT, OM, SA, SY, TR, YE);</li>\n      <li>Naproscript (ET);</li>\n      <li>Naprosyn (AE, AU, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, CZ, DK, EC, EG, ES, ET, FI, GB, GH, GM, GN, GR, GY, HU, IE, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, OM, PE, PT, PY, QA, RU, SA, SC, SD, SE, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Naprosyn LE (TH);</li>\n      <li>Naprosyn LLE (PH);</li>\n      <li>Naprosyn LLE Forte (PH);</li>\n      <li>Naprosyn SR (AU);</li>\n      <li>Naprosyne (BE, FR, LU, NL);</li>\n      <li>Naprox (LK, QA);</li>\n      <li>Naproxi 250 (IL);</li>\n      <li>Naproxi 500 (IL);</li>\n      <li>Naprux (AR);</li>\n      <li>Naxen (LK, MX, NZ);</li>\n      <li>Naxen F (KR);</li>\n      <li>Naxen-F CR (KR);</li>\n      <li>Naxopren (FI);</li>\n      <li>Naxyn 250 (IL);</li>\n      <li>Naxyn 500 (IL);</li>\n      <li>Noflam (NZ);</li>\n      <li>Noken (JO);</li>\n      <li>Nopain (QA);</li>\n      <li>Nopen (PH);</li>\n      <li>Norswel (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Novaxen (MX);</li>\n      <li>Nycopren (AT, DK, FI);</li>\n      <li>Pairox (BD);</li>\n      <li>Penles (PH);</li>\n      <li>Prexan (IT);</li>\n      <li>Priaxen (BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, SR, TN, TR, TT, TZ, UG, ZM, ZW);</li>\n      <li>Primeral (IT);</li>\n      <li>Prodexin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Progend (BD);</li>\n      <li>Proken (AE, BH, JO, LB, QA, SA);</li>\n      <li>Pronaxen (SE);</li>\n      <li>Proxen (AE, AT, BH, CH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TW, VN, YE);</li>\n      <li>Reuxen (RO);</li>\n      <li>Safrosyn S (MY);</li>\n      <li>Seladin (MY, SG);</li>\n      <li>Sindolan (EC);</li>\n      <li>Snofin (HK);</li>\n      <li>Soden (SG);</li>\n      <li>Sutolin (TW);</li>\n      <li>Synflex (AU);</li>\n      <li>Tormax (LK);</li>\n      <li>U-Ritis (TW);</li>\n      <li>Ultranax (BD);</li>\n      <li>Veradol (AR);</li>\n      <li>Xenar (IT);</li>\n      <li>Xenifar (ID, IE);</li>\n      <li>Xynap (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aleve caplets (naproxen) [prescribing information]. Bayer Healthcare; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alevel liquid gels (naproxen) [prescribing information]. Bayer Healthcare; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aleve tablets (naproxen) [prescribing information]. Bayer Healthcare; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amundsen S, Nordeng H, Nezvalov&aacute;-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. <i>Nat Rev Neurol</i>. 2015;11(4):209-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/25776823/pubmed\" target=\"_blank\" id=\"25776823\">25776823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anttila M, Haataja M, Kasanen A. Pharmacokinetics of naproxen in subjects with normal and impaired renal function. <i>Eur J Clin Pharmacol</i>. 1980;18(3):263-268.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/7439246/pubmed\" target=\"_blank\" id=\"7439246\">7439246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde CB, Sethna NF. Analgesics for the treatment of pain in children. <i>N Engl J Med</i>. 2002;347(14):1094-1103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/12362012/pubmed\" target=\"_blank\" id=\"12362012\">12362012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340. doi: 10.1097/BOR.0000000000000054.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/24663106/pubmed\" target=\"_blank\" id=\"24663106\">24663106</a>]</span><span class=\"doi\">10.1097/BOR.0000000000000054</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>J Am Coll Cardiol</i>, 2008, 52(18):1502-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/19017521/pubmed\" target=\"_blank\" id=\"19017521\">19017521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/23558845/pubmed\" target=\"_blank\" id=\"23558845\">23558845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Naproxen: a review of its pharmacological properties and therapeutic efficacy and use. <i>Drugs</i>. 1975;9(5):326-363.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/1097233/pubmed\" target=\"_blank\" id=\"1097233\">1097233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EC-Naprosyn tablets (naproxen) [prescribing information]. Alpharetta, GA: Canton Laboratories, LLC; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8422565\"></a>Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases. <i>Br J Rheumatol</i>. 1993;32(1):73-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/8422565/pubmed\" target=\"_blank\" id=\"8422565\">8422565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jamali F, Stevens DR. Naproxen excretion in milk and its uptake by the infant. <i>Drug Intell Clin Pharm</i>. 1983;17(12):910-911.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/6653409/pubmed\" target=\"_blank\" id=\"6653409\">6653409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jamali F, Tam YK, Stevens RD. Naproxen excretion in breast milk and its uptake by suckling infant. <i>Drug Intell Clin Pharm.</i> 1982;16(6):475.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Inter Suppl</i>. 2013;3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lang BA and Finlayson LA, &ldquo;Naproxen-Induced Pseudoporphyria in Patients With Juvenile Rheumatoid Arthritis,&rdquo; <i>J Pediatr</i>, 1994, 124(4):639-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/8151484/pubmed\" target=\"_blank\" id=\"8151484\">8151484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. <i>Paediatr Drugs</i>. 2001;3(11):817-858.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/11735667/pubmed\" target=\"_blank\" id=\"11735667\">11735667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, Academy Of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naprelan controlled release tablets (naproxen) [prescribing information]. Pine Brook NJ: Almatica Pharma, Inc.; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naprosyn tablet (naproxen) [prescribing information]. Mississauga, Ontario: Hoffman-La Roche Limited; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naprelan controlled release tablets (naproxen) [prescribing information]. Waukegan IL: Nosco; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naproxen oral suspension (naproxen) [prescribing information]. Columbus, OH: Roxane Laboratories Inc; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naproxen oral suspension (naproxen) [prescribing information]. Columbus, OH: Roxane Laboratories Inc; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naproxen tablet [prescribing information]. Bridgewater NJ: Amneal Pharmaceuticals; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naproxen tablet (naproxen) [prescribing information]. Selersville, PA: Teva Pharmaceuticals USA; July 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&quot; 6th ed, Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saavedra Salinas M&Aacute;, Barrera Cruz A, Cabral Casta&ntilde;eda AR, et al. Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part II. <i>Reumatol Clin</i>. 2015;11(5):305-315. doi: 10.1016/j.reuma.2014.12.004.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/25683368/pubmed\" target=\"_blank\" id=\"25683368\">25683368</a>]</span><span class=\"doi\">10.1016/j.reuma.2014.12.004</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sammaritano LR, Bermas BL. Rheumatoid arthritis medications and lactation. <i>Curr Opin Rheumatol</i>. 2014;26(3):354-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/24614280/pubmed\" target=\"_blank\" id=\"24614280\">24614280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uziel Y, Hashkes PJ, Kassem E, et al, &ldquo;The Use of Naproxen in the Treatment of Children With Rheumatic Fever,&rdquo; <i>J Pediatr</i>, 2000, 137(2):269-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/10931426 /pubmed\" target=\"_blank\" id=\"10931426 \">10931426 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wells TG, Mortensen ME, Dietrich A, et al, &ldquo;Comparison of the Pharmacokinetics of Naproxen Tablets and Suspension in Children,&rdquo; <i>J Clin Pharmacol</i>, 1994, 34(1):30-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/8132849/pubmed\" target=\"_blank\" id=\"8132849\">8132849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naproxen-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12630 Version 279.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709165\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F199854\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F199855\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054290\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054283\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F199830\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F199815\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F23884418\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874744\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054294\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F199849\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054293\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F199915\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F199912\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F199837\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F199819\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26018318\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F199900\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F199824\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F199850\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7696306\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054289\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F199818\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F199836\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F199839\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F199841\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12630|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=naproxen-drug-information\" class=\"drug drug_general\">Naproxen: Drug information</a></li><li><a href=\"topic.htm?path=naproxen-patient-drug-information\" class=\"drug drug_patient\">Naproxen: Patient drug information</a></li></ul></div></div>","javascript":null}